Antiretroviral Therapy Concentrations Differ in Gut vs. Lymph Node Tissues and Are Associated With HIV Viral Transcription by a Novel RT-ddPCR Assay.

BACKGROUND Most HIV-infected cells during antiretroviral therapy (ART) persist in lymphoid tissues. Studies disagree on whether suboptimal tissue ART concentrations contribute to ongoing HIV replication during viral suppression. METHODS We performed a cross-sectional study in virally-suppressed HIV+ participants measuring lymphoid tissue ART [darunavir (DRV), atazanavir (ATV), and raltegravir (RAL)] concentrations by LC-MS/MS assay. Tissue and plasma ART concentrations were used to estimate TPRs and drug-specific tissue:inhibitory concentration ratios (TICs). HIV DNA and sequentially produced HIV RNA transcripts were quantified from rectal biopsies using droplet digital PCR (ddPCR) assays. RESULTS Tissue samples were collected in duplicate from 19 participants: 38 rectal, 8 ileal (4 RAL, 2 DRV, 2 ATV), and 6 lymph node (4 RAL, 2 DRV) samples. Overall, median TICs were higher for RAL than DRV or ATV (both P = 0.006). Median TICs were lower in lymph nodes vs. ileum (0.49 vs. 143, P = 0.028) or rectum (33, P = 0.019), and all ART levels were below target concentrations. Higher rectal TICs were associated with lower HIV RNA transcripts (read-through, long LTR, and Nef, P all < 0.026) and a lower long LTR RNA/long LTR DNA ratio (P = 0.021). CONCLUSIONS We observed higher tissue ART concentrations in ileum and rectum compared with lymph nodes. We observed higher HIV transcription in participants with lower rectal ART concentrations. These findings add to the limited data supporting the idea that viral transcription may be influenced by ART concentrations in lymphoid tissues. Further exploration of tissue pharmacokinetics is needed in future HIV eradication strategies.

[1]  B. Berkhout,et al.  Differences in HIV Markers between Infected Individuals Treated with Different ART Regimens: Implications for the Persistence of Viral Reservoirs , 2020, Viruses.

[2]  P. Prathipati,et al.  Long‐acting parenteral combination antiretroviral loaded nano‐drug delivery system to treat chronic HIV‐1 infection: A humanized mouse model study , 2018, Antiviral research.

[3]  J. Nelson,et al.  Virological and Immunological Responses to Raltegravir and Dolutegravir in the Gut-Associated Lymphoid Tissue of HIV-Infected Men and Women , 2018, Antiviral therapy.

[4]  J. Wong,et al.  HIV latency in isolated patient CD4+ T cells may be due to blocks in HIV transcriptional elongation, completion, and splicing , 2018, Science Translational Medicine.

[5]  Xia Wang,et al.  Influence of raltegravir intensification on viral load and 2-LTR dynamics in HIV patients on suppressive antiretroviral therapy. , 2017, Journal of theoretical biology.

[6]  J. Mellors,et al.  Ultrasensitive single-genome sequencing: accurate, targeted, next generation sequencing of HIV-1 RNA , 2016, Retrovirology.

[7]  R. Siliciano,et al.  Defective proviruses rapidly accumulate during acute HIV-1 infection , 2016, Nature Medicine.

[8]  J. Lifson,et al.  Defining HIV and SIV Reservoirs in Lymphoid Tissues , 2016, Pathogens & immunity.

[9]  C. Larsen,et al.  Long-Term Mortality in HIV-Infected Individuals 50 Years or Older: A Nationwide, Population-Based Cohort Study , 2016, Journal of acquired immune deficiency syndromes.

[10]  Trevor Bedford,et al.  Persistent HIV-1 replication maintains the tissue reservoir during therapy , 2015, Nature.

[11]  Rebecca Hoh,et al.  Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study. , 2015, The lancet. HIV.

[12]  C. Fletcher,et al.  A rapid spin through oil results in higher cell-associated concentrations of antiretrovirals compared with conventional cell washing. , 2015, Bioanalysis.

[13]  D. Hazuda,et al.  A Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals , 2015, EBioMedicine.

[14]  P. Hunt.  HIV and aging: emerging research issues. , 2014, Current opinion in HIV and AIDS.

[15]  L. Fändriks,et al.  Surface area of the digestive tract – revisited , 2014, Scandinavian journal of gastroenterology.

[16]  A. Kashuba,et al.  Pharmacokinetics of Antiretrovirals in Genital Secretions and Anatomic Sites of HIV Transmission: Implications for HIV Prevention , 2014, Clinical Pharmacokinetics.

[17]  A. Telenti,et al.  Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals. , 2014, The Journal of antimicrobial chemotherapy.

[18]  J. Wong,et al.  Advantages of using the QIAshredder instead of restriction digestion to prepare DNA for droplet digital PCR. , 2014, BioTechniques.

[19]  J. Mellors,et al.  Lack of Detectable HIV-1 Molecular Evolution during Suppressive Antiretroviral Therapy , 2014, PLoS pathogens.

[20]  Alan S Perelson,et al.  Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues , 2014, Proceedings of the National Academy of Sciences.

[21]  P. Lemey,et al.  The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time , 2013, Proceedings of the National Academy of Sciences.

[22]  Rebecca Hoh,et al.  Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. , 2013, The Journal of infectious diseases.

[23]  Myron S. Cohen,et al.  Antiretroviral Pharmacology in Mucosal Tissues , 2013, Journal of acquired immune deficiency syndromes.

[24]  B. Clotet,et al.  Dynamics of CD8 T-Cell Activation After Discontinuation of HIV Treatment Intensification , 2013, Journal of acquired immune deficiency syndromes.

[25]  N. Shaheen,et al.  Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure , 2013, AIDS.

[26]  R. Siliciano,et al.  Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies , 2013, PLoS pathogens.

[27]  J. Mullins,et al.  An Increasing Proportion of Monotypic HIV-1 DNA Sequences during Antiretroviral Treatment Suggests Proliferation of HIV-Infected Cells , 2012, Journal of Virology.

[28]  C. Fletcher,et al.  A novel ultrasensitive LC-MS/MS assay for quantification of intracellular raltegravir in human cell extracts. , 2012, Journal of pharmaceutical and biomedical analysis.

[29]  X. Panhard,et al.  Effect of Adherence as Measured by MEMS, Ritonavir Boosting, and CYP3A5 Genotype on Atazanavir Pharmacokinetics in Treatment‐Naive HIV‐Infected Patients , 2012, Clinical pharmacology and therapeutics.

[30]  M. Lederman,et al.  Towards an HIV cure: a global scientific strategy , 2012, Nature Reviews Immunology.

[31]  J. Eron,et al.  Pharmacokinetics and Pharmacodynamics of Once-Daily versus Twice-Daily Raltegravir in Treatment-Naïve HIV-Infected Patients , 2012, Antimicrobial Agents and Chemotherapy.

[32]  M. Markowitz,et al.  Absence of HIV-1 Evolution in the Gut-Associated Lymphoid Tissue from Patients on Combination Antiviral Therapy Initiated during Primary Infection , 2012, PLoS pathogens.

[33]  Myron S. Cohen,et al.  Penetration of Tenofovir and Emtricitabine in Mucosal Tissues: Implications for Prevention of HIV-1 Transmission , 2011, Science Translational Medicine.

[34]  B. Gazzard,et al.  Pharmacokinetics of Once-Daily Darunavir-Ritonavir and Atazanavir-Ritonavir over 72 Hours following Drug Cessation , 2011, Antimicrobial Agents and Chemotherapy.

[35]  C. B. Hare,et al.  Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. , 2010, The Journal of infectious diseases.

[36]  C. B. Hare,et al.  Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy , 2010, AIDS.

[37]  M. Lederman,et al.  The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial , 2010, PLoS medicine.

[38]  S J Gange,et al.  Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  A. Kashuba,et al.  Development of an LC-MS method for measuring TNF in human vaginal tissue. , 2010, Journal of chromatographic science.

[40]  S J Gange,et al.  Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy , 2009, Proceedings of the National Academy of Sciences.

[41]  J. Mellors,et al.  Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy , 2008, Proceedings of the National Academy of Sciences.

[42]  O. Cars,et al.  Tissue concentrations: do we ever learn? , 2007, The Journal of antimicrobial chemotherapy.

[43]  A. Badley,et al.  HIV protease inhibitors impact on apoptosis. , 2008, Medicinal chemistry (Shariqah (United Arab Emirates)).

[44]  T. Schacker,et al.  Inguinal lymph node biopsy in patients infected with the human immunodeficiency virus is safe. , 2007, Surgical infections.

[45]  W. Mothes,et al.  Retroviruses can establish filopodial bridges for efficient cell-to-cell transmission , 2007, Nature Cell Biology.

[46]  Claus O. Wilke,et al.  Residual Human Immunodeficiency Virus Type 1 Viremia in Some Patients on Antiretroviral Therapy Is Dominated by a Small Number of Invariant Clones Rarely Found in Circulating CD4+ T Cells , 2006, Journal of Virology.

[47]  John W. Mellors,et al.  New Real-Time Reverse Transcriptase-Initiated PCR Assay with Single-Copy Sensitivity for Human Immunodeficiency Virus Type 1 RNA in Plasma , 2003, Journal of Clinical Microbiology.

[48]  Steven Wolinsky,et al.  Persistent abnormalities in lymphoid tissues of human immunodeficiency virus-infected patients successfully treated with highly active antiretroviral therapy. , 2002, The Journal of infectious diseases.

[49]  Steven Wolinsky,et al.  Collagen deposition in HIV-1 infected lymphatic tissues and T cell homeostasis. , 2002, The Journal of clinical investigation.

[50]  A B Brill,et al.  A new rectal model for dosimetry applications. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[51]  Alan S. Perelson,et al.  Decay characteristics of HIV-1-infected compartments during combination therapy , 1997, Nature.